We help founders transform industries.

Venture investment in technology and healthcare

GLOBAL MULTI-STAGE INVESTOR, WORLD-CLASS NETWORK

Approach

Sixty Degree Capital invests in companies creating meaningful change in their industries, across sectors (software, digital infrastructure, healthcare, biotech) and across stages (as early as Series A, as late as pre-IPO).

Advantage

We have a world-class network, specialized in-house expertise, and relationships with marquee investors. This differentiation enables us to support our portfolio companies and generate exceptional returns for our LPs.

Our Portfolio

Arcellx logo
Antios Therapeutics logo
Bionaut Labs logo
Clearcover logo
Cincor logo
Engage Therapeutics logo
Everly Health logo
GrubMarket logo
Inspirna logo
Korro
Libra Therapeutics logo
Lime logo
Macrometa logo
Miovision logo
Monte Rosa Therapeutics
Northern Biologics logo
Pipeline logo
Radius Agent and Realty logo
Reflexion logo
Schrodinger logo
Tact.ai logo
Tknife Therapeutics logo
TransThera logo
Turnstone Biologics logo
Veem logo
Everly Health logo
Lime logo
Macrometa logo
Miovision logo
Radius Agent and Realty logo
Tact.ai logo
Veem logo
Bionaut Labs logo
Inspirna logo
Korro
Libra Therapeutics logo
Reflexion logo
Tknife Therapeutics logo
TransThera logo
Turnstone Biologics logo
Cincor logo
Engage Therapeutics logo
Monte Rosa Therapeutics
Northern Biologics logo
Schrodinger logo

News

News

Antios Therapeutics Raises $96 Million in a Series B Financing

Funding will support the Phase 2 clinical program of ATI-2173 in HBV Soleus Capital led the round with new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as Altium Capital, Amzak Health, Granite Point Capital Management, LP, and Life Sci Venture Partners and participating existing investors Lumira Ventures,…
Read More

Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies

GAITHERSBURG, Md., April 13, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase…
Read More

Arcellx Announces Executive Appointments

Dr. Christopher Heery joins as Chief Medical Officer and Neeraj Teotia joins as Chief Commercial Officer GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s leadership team. Dr. Christopher Heery has been named Chief Medical…
Read More

Send us Message

  • This field is for validation purposes and should be left unchanged.